Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

This analysis is based on information available up to January 17, 2025, and market conditions may have changed since then. Gain an edge in your investment decisions with InvestingPro’s in-depth ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.

Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

The shares of Danish weight-loss drug maker Novo Nordisk (NVO) are retreating 5% today, while Eli Lilly (LLY), which makes a ...

The best companies will pay you to own them, sharing their profits via dividends. These high-quality stocks continuously grow ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...